Patent 7501452 was granted and assigned to Endo Pharmaceuticals on March, 2009 by the United States Patent and Trademark Office.
Xerostomia is treated with a sulfur-containing antioxidant, such as N-acetylcysteine. Delivery compositions including polyoxyalkylene block copolymers may be used, which may be formulated to exhibit reverse-thermal viscosity behavior.